AAAAAA
Results: 1-25/52
Authors:
IYENGAR S
MAZUMDAR M
Citation: S. Iyengar et M. Mazumdar, A SADDLE-POINT APPROXIMATION FOR CERTAIN MULTIVARIATE TAIL PROBABILITIES, SIAM journal on scientific computing, 19(4), 1998, pp. 1234-1244
Authors:
SHIH FR
MAZUMDAR M
Citation: Fr. Shih et M. Mazumdar, AN ANALYTICAL FORMULA FOR THE MEAN AND VARIANCE MARGINAL COSTS FOR A POWER-GENERATION SYSTEM, IEEE transactions on power systems, 13(3), 1998, pp. 731-737
Authors:
BAJORIN DF
MCCAFFREY JA
HILTON S
MAZUMDAR M
KELLY WK
SCHER HI
SPICER J
HERR H
HIGGINS G
Citation: Df. Bajorin et al., TREATMENT OF PATIENTS WITH TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIAL TRACT WITH IFOSFAMIDE, PACLITAXEL, AND CISPLATIN - A PHASE-II TRIAL, Journal of clinical oncology, 16(8), 1998, pp. 2722-2727
Authors:
BAJORIN DF
MAZUMDAR M
MEYERS M
MOTZER RJ
VLAMIS V
LIN P
BOSL GJ
Citation: Df. Bajorin et al., METASTATIC GERM-CELL TUMORS - MODELING FOR RESPONSE TO CHEMOTHERAPY, Journal of clinical oncology, 16(2), 1998, pp. 707-715
Authors:
AKHURST T
MAZUMDAR M
LARSON S
MACAPINLAC H
IMBRIACO M
FONG Y
KEMENY N
COHEN A
Citation: T. Akhurst et al., POTENTIALLY RESECTABLE COLORECTAL-CANCER - WHAT DOES THAT EQUIVOCAL FDG PET REPORT MEAN TO ME AS A REFERRING PHYSICIAN, The Journal of nuclear medicine, 39(5), 1998, pp. 1111-1111
Authors:
MCCAFFREY JA
DODD PM
HERR H
VLAMIS V
MAZUMDAR M
HIGGINS G
SCHER HI
BAJORIN DF
Citation: Ja. Mccaffrey et al., ANATOMIC SITE OF PRIMARY TRANSITIONAL-CELL CARCINOMA (TCC) DOES NOT AFFECT PROBABILITY OF RESPONSE TO M-VAC OR SURVIVAL, The Journal of urology, 159(5), 1998, pp. 634-634
Authors:
DODD PM
MCCAFFREY JA
HERR H
VLAMIS V
MAZUMDAR M
HIGGINS G
SCHER HI
BAJORIN DF
Citation: Pm. Dodd et al., POSTCHEMOTHERAPY SURGERY AFTER M-VAC IN PATIENTS (PTS) WITH METASTATIC TRANSITIONAL-CELL CARCINOMA (TCC) CAN RESULT IN LONG-TERM SURVIVAL, The Journal of urology, 159(5), 1998, pp. 636-636
Authors:
MOTZER RJ
AMSTERDAM A
PRIETO V
SHEINFELD J
MURTY VVS
MAZUMDAR M
BOSL GJ
CHAGANTI RSK
REUTER VE
Citation: Rj. Motzer et al., TERATOMA WITH MALIGNANT TRANSFORMATION - DIVERSE MALIGNANT HISTOLOGIES ARISING IN MEN WITH GERM-CELL TUMORS, The Journal of urology, 159(1), 1998, pp. 133-138
Authors:
MAZUMDAR M
CROSS RA
Citation: M. Mazumdar et Ra. Cross, ENGINEERING A LEVER INTO THE KINESIN NECK, The Journal of biological chemistry, 273(45), 1998, pp. 29352-29359
Authors:
RAJGOPAL J
MAZUMDAR M
Citation: J. Rajgopal et M. Mazumdar, MINIMUM-COST COMPONENT TEST PLANS FOR EVALUATING RELIABILITY OF A HIGHLY RELIABLE PARALLEL SYSTEM, Naval research logistics, 44(5), 1997, pp. 401-418
Authors:
SCHER HI
LIEBERTZ C
KELLY WK
MAZUMDAR M
BRETT C
SCHWARTZ L
KOLVENBAG G
SHAPIRO L
SCHWARTZ M
Citation: Hi. Scher et al., BICALUTAMIDE FOR ADVANCED PROSTATE-CANCER - THE NATURAL VERSUS TREATED HISTORY OF DISEASE, Journal of clinical oncology, 15(8), 1997, pp. 2928-2938
Authors:
MOTZER RJ
MAZUMDAR M
BAJORIN DF
BOSL GJ
LYN P
VLAMIS V
Citation: Rj. Motzer et al., HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN FIRST-LINE THERAPY FOR PATIENTS WITH POOR-RISK GERM-CELL TUMORS, Journal of clinical oncology, 15(7), 1997, pp. 2546-2552
LONG-TERM FOLLOW-UP OF PATIENTS WITH GOOD-RISK GERM-CELL TUMORS TREATED WITH ETOPOSIDE AND CISPLATIN
Authors:
XIAO H
MAZUMDAR M
BAJORIN DF
SAROSDY M
VLAMIS V
SPICER J
FERRARA J
BOSL GJ
MOTZER RJ
Citation: H. Xiao et al., LONG-TERM FOLLOW-UP OF PATIENTS WITH GOOD-RISK GERM-CELL TUMORS TREATED WITH ETOPOSIDE AND CISPLATIN, Journal of clinical oncology, 15(7), 1997, pp. 2553-2558
Authors:
MCCAFFREY JA
MAZUMDAR M
BAJORIN DF
BOSL GJ
VLAMIS V
MOTZER RJ
Citation: Ja. Mccaffrey et al., IFOSFAMIDE-CONTAINING AND CISPLATIN-CONTAINING CHEMOTHERAPY AS FIRST-LINE SALVAGE THERAPY IN GERM-CELL TUMORS - RESPONSE AND SURVIVAL, Journal of clinical oncology, 15(7), 1997, pp. 2559-2563
Authors:
MCCAFFREY JA
HILTON S
MAZUMDAR M
SADAN S
HEINEMAN M
HIRSCH J
KELLY WK
SCHER HI
BAJORIN DF
Citation: Ja. Mccaffrey et al., PHASE-II RANDOMIZED TRIAL OF GALLIUM NITRATE PLUS FLUOROURACIL VERSUSMETHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN IN PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA, Journal of clinical oncology, 15(6), 1997, pp. 2449-2455
Authors:
MCCAFFREY JA
HILTON S
MAZUMDAR M
SADAN S
KELLY WK
SCHER HI
BAJORIN DF
Citation: Ja. Mccaffrey et al., PHASE-II TRIAL OF DOCETAXEL IN PATIENTS WITH ADVANCED OR METASTATIC TRANSITIONAL-CELL CARCINOMA, Journal of clinical oncology, 15(5), 1997, pp. 1853-1857
Authors:
MEAD GM
STENNING SP
COOK P
FOSSA SD
HORWICH A
KAYE SB
OLIVER RTD
DEMULDER PHM
DEWIT R
STOTER G
SYLVESTER RJ
BAJORIN DF
BOSL GJ
MAZUMDAR M
NICHOLS CR
AMATO R
PIZZOCARO G
DROZ JP
KRAMAR A
DAUGAARD G
CORTESFUNES H
PAZARES L
LEVI JA
COLLS BM
HARVEY VJ
COPPIN C
Citation: Gm. Mead et al., INTERNATIONAL GERM-CELL CONSENSUS CLASSIFICATION - A PROGNOSTIC FACTOR-ERASED STAGING SYSTEM FOR METASTATIC GERM-CELL CANCERS, Journal of clinical oncology, 15(2), 1997, pp. 594-603
Authors:
BERG WJ
SCHWARTZ LH
AMSTERDAM A
MAZUMDAR M
VLAMIS V
LAW TM
NANUS DM
MOTZER RJ
Citation: Wj. Berg et al., A PHASE-II STUDY OF 13-CIS-RETINOIC ACID IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, Investigational new drugs, 15(4), 1997, pp. 353-355
Authors:
DHAR S
PAUL S
MAZUMDAR M
BANERJEE S
Citation: S. Dhar et al., EFFECT OF ER DOPANT ON THE PROPERTIES OF IN0.53GA0.47AS LAYERS GROWN BY LIQUID-PHASE EPITAXY, Journal of applied physics, 81(5), 1997, pp. 2391-2395
Authors:
GORLICK R
GOKER E
TRIPPETT T
STEINHERZ P
ELISSEYEFF Y
MAZUMDAR M
FLINTOFF WF
BERTINO JR
Citation: R. Gorlick et al., DEFECTIVE TRANSPORT IS A COMMON MECHANISM OF ACQUIRED METHOTREXATE RESISTANCE IN ACUTE LYMPHOCYTIC-LEUKEMIA AND IS ASSOCIATED WITH DECREASED REDUCED FOLATE CARRIER EXPRESSION, Blood, 89(3), 1997, pp. 1013-1018
Authors:
SCHER HI
MAZUMDAR M
KELLY WK
Citation: Hi. Scher et al., CLINICAL-TRIALS IN RELAPSED PROSTATE-CANCER - DEFINING THE TARGET, Journal of the National Cancer Institute, 88(22), 1996, pp. 1623-1634
Authors:
MAZUMDAR M
Citation: M. Mazumdar, COMPUTATION OF POWER-GENERATION SYSTEM PRODUCTION COSTS, IEEE transactions on power systems, 11(2), 1996, pp. 696-701
Authors:
MOTZER RJ
MAZUMDAR M
BOSL GJ
BAJORIN DF
AMSTERDAM A
VLAMIS V
Citation: Rj. Motzer et al., HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND CYCLOPHOSPHAMIDE FOR PATIENTS WITH REFRACTORY GERM-CELL TUMORS - TREATMENT RESULTS AND PROGNOSTIC FACTORS FOR SURVIVAL AND TOXICITY, Journal of clinical oncology, 14(4), 1996, pp. 1098-1105
Authors:
PUC HS
HEELAN R
MAZUMDAR M
HERR H
SCHEINFELD J
VLAMIS V
BAJORIN DF
BOSL GJ
MENCEL P
MOTZER RJ
Citation: Hs. Puc et al., MANAGEMENT OF RESIDUAL MASS IN ADVANCED SEMINOMA - RESULTS AND RECOMMENDATIONS FROM THE MEMORIAL SLOAN-KETTERING CANCER CENTER, Journal of clinical oncology, 14(2), 1996, pp. 454-460
Authors:
KAPOOR A
MAZUMDAR M
Citation: A. Kapoor et M. Mazumdar, APPROXIMATE COMPUTATION OF THE VARIANCE OF ELECTRIC-POWER GENERATION SYSTEM PRODUCTION COSTS, INTERNATIONAL JOURNAL OF ELECTRICAL POWER AND ENERGY SYSTEMS, 18(4), 1996, pp. 229-238